Modified IgG2 Antibodies for FcγR-Independent Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of understanding regarding the optimal antibody isotypes for achieving agonistic or antagonistic properties in therapeutic antibodies, particularly for human therapy, and how antibody isotype affects therapeutic outcomes for agonistic or antagonistic mAbs or fusion proteins targeting immunostimulatory receptors.
Innovation Solution
The development of novel antibodies and fusion proteins with specific mutations in the human IgG2 constant regions that manipulate the hinge and CH1 disulfide bonds to 'lock' the antibody into either a more flexible 'h2A' or compact 'h2B' conformation, enhancing agonistic or antagonistic properties independently of FcγR interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human IgG2 is used to deliver agonistic activity to anti-CD40 antibodies, then FcγR-independent agonistic activity is achieved, but the activity is dependent on the precise arrangement of hinge and CH1 disulfide bonds which creates conformational heterogeneity
Solution Approach 1:
The patent applies parameter changes by mutating specific cysteine residues (Cys232, Cys233, Cys236, Cys239) in the hinge region to alter disulfide bond arrangement. This locks the antibody into defined conformations (h2A or h2B), converting conformational heterogeneity into structural homogeneity while preserving agonistic activity. The mutation of cysteine residues changes the chemical parameters of disulfide bonding, enabling control over molecular conformation.
Solution Approach 2:
The patent segments the antibody structure by focusing modifications specifically on the hinge and CH1 regions while leaving the FcγR interaction domains intact. This segmentation allows independent optimization of conformational stability without affecting the core agonistic mechanism, resolving the contradiction between activity and homogeneity.
2Stability of the object's composition
If mutations are introduced to lock the antibody into h2A or h2B conformation, then conformational homogeneity is achieved, but the complexity of antibody design and manufacturing increases
Solution Approach 1:
The patent uses targeted parameter changes by mutating only four specific cysteine residues in the hinge region. This limited set of parameter changes achieves conformational locking without requiring extensive redesign of the entire antibody molecule, thereby managing design complexity while achieving homogeneity.
Solution Approach 2:
The patent creates universal design templates (h2A and h2B) that can be applied to different anti-CD40 antibody variants. Once the hinge region is engineered with the appropriate disulfide bond arrangement, the same design principle can be universally applied across multiple antibody candidates, reducing overall design complexity through standardization.
3Reliability
If conventional isotypes (human IgG1 or mouse IgG2a) are used, then FcγR interactions are engaged for agonistic activity, but the therapeutic efficacy is limited by high activatory/inhibitory FcγR binding ratio
Solution Approach 1:
The patent changes the isotype parameter from conventional IgG1 or mouse IgG2a to human IgG2 with engineered hinge conformations. This parameter change fundamentally alters the FcγR binding characteristics, achieving agonistic activity through a mechanism that is independent of FcγR interactions, thereby eliminating the harmful inhibitory binding.
Solution Approach 2:
The patent converts the potentially harmful FcγR-independent mechanism into a benefit by engineering the hinge region to stabilize conformations that enhance agonistic activity without requiring FcγR engagement. The low affinity for FcγR, which could be seen as a limitation, is transformed into an advantage by enabling alternative agonistic pathways that avoid inhibitory FcγR binding.
Data Source
Figure 1A~1F
Figure 2A~2C
Figure 3A~3D
AI summary
Through a combination of in vitro and in vivo approaches, the inventors show that human lgG2 (h2) delivers unique FcyR-independent agonistic activity to anti-CD40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1BB and CD28. Investigation of an anti-human CD40 mAb, LOB7.4, revealed that the unique activity of h2 was dependent upon the precise arrangement of hinge and CH1 disulfide bonds. Chemical 'shuffling' or mutagenesis to 'lock' LOB7.4 into either a more flexible 'h2A' or more compact 'h2B' conformation endowed antagonistic and agonistic properties, respectively. Engineering of h2 in this way allows development of reagents with either immunostimulatory or immunosuppressive characteristics, with direct implication for the design of therapeutic mAb agents and fusion proteins.